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ABSTRACT
Previous studies suggested that bisphosphonate zoledronic acid exerts an anti-
tumor effect by interacting with the microenvironment. In this study, we aimed to 
elucidate the mechanism behind the anti-breast cancer effect of zoledronic acid.
Here we showed that zoledronic acid did not influence in vitro human breast 
cancer cell survival, but did affect human stromal cell survival. Breast cancer cell 
death in co-culture with stromal cells was analyzed in vitro by fluorescent microscopy 
and flowcytometry analysis. In co-culture, the addition of stromal cells to breast 
cancer cells induced tumor cell death by zoledronic acid, which was abolished by 
transforming growth factor (TGF)-β. In the in vivo chicken chorioallantoic membrane 
model, zoledronic acid reduced the breast cancer cells fraction per tumor only in 
the presence of human stromal cells. Zoledronic acid decreased TGF-β excretion 
by stromal cells and co-cultures. Moreover, supernatant of zoledronic acid treated 
stromal cells reduced phospho-Smad2 protein levels in breast cancer cells. Thus, 
zoledronic acid exerts an anti-breast cancer effect via stromal cells, accompanied 
by decreased stromal TGF-β excretion and reduced TGF-β signaling in cancer cells.
INTRODUCTION
Breast cancer accounts for the highest cancer 
incidence and cancer mortality among women worldwide 
[1]. Despite great advances in breast cancer treatment, 
including increasingly targeted systemic treatment, 
development of metastatic disease still cannot be 
prevented in all patients. Therefore, there is a continuous 
search for new treatment strategies that may increase the 
effect of systemic therapy. Currently, the importance of 
the tumor microenvironment in which immune cells, 
fibroblasts, adipose cells and endothelial cells are involved 
in tumor growth and metastasis has become more evident 
[2]. Furthermore, preclinical studies have also shown that 
the microenvironment is an important regulator of cancer 
cell related drug sensitivity [3]. This provides the rational 
for targeting not only the cancer cells, but also the tumor 
microenvironment to improve treatment options for breast 
cancer patients.
Bisphosphonates, currently used as supportive 
treatment in breast cancer patients with bone metastases, 
have a potential anti-cancer effect via microenvironmenal 
cells. A recent meta-analysis [4] concluded that this class 
of compounds induces survival benefit in postmenopausal 
women being treated for breast cancer. Although the 
anti-cancer effect of bisphosphonates is apparently not 
limited to their anti-resorptive role in bone lesions [5], 
the mechanism behind this anti-cancer response remains 
unclear. Recent research has elucidated parts of this 
mystery by showing that the bisphosphonates risedronate 
and pamidronate are internalized by tumor-associated 
macrophages, but not by mouse tumor cells 4T1 [6]. 
The authors concluded that these compounds target 
macrophages, but not tumor cells. These results support 
an indirect anti-tumor effect of bisphosphonates. 
It would be of great benefit for further optimization 
when this indirect anti-tumor effect would be further 
clarified. For this, optimal preclinical models containing 
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both human cancer cells and human stromal components 
are essential [7, 8]. At present optimal preclinical models 
are lacking. In vitro culture models are mostly too 
simplified and traditional mouse models fall short in this 
setting, since mouse stromal infiltration into human cell 
line xenografts as well as into patient derived xenografts 
occur to a high extent [9, 10].
We have optimized the chorioallantoic membrane 
(CAM) model, which makes it possible to study the 
direct interactions between human tumor cells and 
human stromal cells in vivo in an immune deprived 
setting. By using in vitro and in vivo models consisting 
of human stromal cells as well as human breast cancer 
cells, we studied the role of stromal cells in breast 
cancer bisphosphonate sensitivity. Our research provides 
functional evidence of the role of stromal cells in 
zoledronic acid (ZOL) mediated breast cancer cell death. 
RESULTS
Stromal cells are required for the anti-breast 
cancer effect of ZOL in vitro
High concentrations of ZOL were required to 
decrease cell survival of the human breast cancer cell 
lines. The MCF-7 line was not sensitive to ZOL treatment. 
The human breast tumor cell lines SCP2, SUM-149, H2N 
and MDA-MB-231 had an IC50 of 486, 194, 155 and 86 
µM respectively. However, ZOL affected stromal cell 
survival at concentrations far below the concentrations 
directly affecting breast cancer cell lines: IC50 for human 
stromal cell line Hs27a was reached at a concentration of 
only 8 µM. In addition, the macrophage cell line RAW 
264.7 was also very sensitive to ZOL treatment, with an 
IC50 of 19 µM (Figure 1).
Figure 1: Relative survival after exposure to zoledronic acid. Relative survival (%) curves after 96 hours of exposure to 1 – 1000 
µM zoledronic acid of the stromal cell lines Hs27a and RAW 264.7 and the breast cancer cell lines MCF-7, SUM-149, SCP2, H2N and 
MDA-MB-231. The half maximal inhibitory concentration (IC50) is depicted for every cell line (dashed red line). Data are represented as 
mean ± SD.
Oncotarget24438www.impactjournals.com/oncotarget
To investigate the indirect effects of ZOL, we used 
a fluorescence-based in vitro co-culture model. In this 
model, SCP2 cells were fluorescently labeled before 
addition to an Hs27a monolayer, in order to distinguish 
tumor cells from stromal cells in cell death assessment. 
Representative nuclear structures of a viable and a dead 
SCP2 cell are depicted in Figure 2A. At 24 hours (Figure 
2B), 50 µM of ZOL increased breast cancer cell death in 
the co-culture group (SCP2 and Hs27a) compared to the 
mono-culture (SCP2) cancer cell group (18.9 ± 1 % vs 6.8 
± 3.5 %, P < 0.01). This effect was ZOL dose-dependent 
in the co-culture group, increasing breast cancer cell death 
to 21.6 ± 0.6 % for 100 µM (P < 0.01) and 27.6 ± 7.8 % (P 
< 0.001) for 500 µM. In mono-culture, increasing the dose 
of ZOL did not increase breast cancer cell death (9.6 ± 1.6 
% for 100 µM and 10.3 ± 1.7 % for 500 µM of ZOL). At 
48 hours, the stromal-dependent breast cancer cell death 
induced by ZOL was even more pronounced than at 24 
Figure 2: In vitro breast cancer cell viability in co-culture after zoledronic acid treatment. A. Representative images 
presenting the assessment of SCP2 cell viability by fluorescence microscopy in the vitro co-culture model at x 40 magnification. The 
overlay shows DAPI nuclear staining (blue) and membrane staining with DiI (red). Nuclei of viable SCP2 cells are round and intact, 
whereas nuclei of dead SCP2 cells are condensed and fragmented. B. Viability (%) of SCP2 mono-culture or co-culture with Hs27a 
stromal cells after 24 and 48 hours of treatment with 0 – 500 µM zoledronic acid analyzed by fluorescent microscopy. C. Viability (%) of 
SCP2 mono-cultures or co-cultured with Hs27a stromal cells after 24 hours of treatment with 0 – 500 µM zoledronic acid determined by 
flowcytometric measurements of DiI and LIVE/DEAD stain. Data are represented as mean ± SD.
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hours (Figure 2B). At a ZOL dose of only 10 µM, breast 
cancer cell death in the co-culture group (23.5 ± 2.8 %) 
was higher compared to the mono-culture group (5.1 ± 3.1 
%, P < 0.001). And the effect became more pronounced as 
the dose of ZOL increased, with breast cancer cell death of 
6.5 ± 2 % for 50 µM, 11.8 ± 2.3 % for 100 µM and 18.4 ± 
3.3 % for 500 µM in the mono-culture group versus 37.0 ± 
0.4 % for 50 µM, 38.0 ± 3.4 % for 100 µM and 44.0 ± 4.6 
% for 500 µM in the co-culture group (P < 0.001 for all 
doses). In mono-cultures of SCP2, ZOL increased breast 
cancer cell death after 48 hours compared to control from 
4.3 ± 1.4 % to 11.8 ± 2.3 % (P < 0.05) for 100 µM and 
18.4 ± 3.3 % (P < 0.001) for 500 µM ZOL (Figure 2B). 
Breast cancer cells death after ZOL treatment was 
also determined by flowcytometry analysis. SCP2 cells 
were labeled with DiI and cell death was determined by 
LIVE/DEAD stain uptake. In the presence of stromal 
cells, SCP2 cell death was induced after treatment with 
ZOL. At 24 hours (Figure 2C), 10 µM of ZOL increased 
breast cancer cell death in the co-culture group (SCP2 and 
Hs27a) compared to the mono-culture (SCP2) group (7.2 
± 3.0% vs 2.5 ± 1.1 %, P < 0.05). This effect was ZOL 
dose-dependent in the co-culture group, increasing breast 
cancer cell death to 11.4 ± 1.4 % for 50 µM (P < 0.001), 
11.6 ± 2.9 % for 100 µM (P < 0.001). For 500 µM no 
difference was seen in SCP2 cell death with and without 
Hs27a cells (39.1 ± 10.5 % vs 26.1 ± 5.1). 
Figure 3: Tumor size and weight after zoledronic acid treatment in vivo. Scatter plots illustrating weight (mg) and size (mm3) 
of in ovo tumors harvested on day 14 after a single gift of zoledronic acid (200 µM) or vehicle (PBS) on day 10. Tumors consisted of SCP2 
alone or SCP2 with Hs27a stromal cells A., B. and MCF-7 alone or MCF-7 with Hs27a stromal cells C., D.. Tumor weight and size are 
depicted for every individual tumor. Data are represented as mean ± SD.
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Figure 4: Breast cancer cell fraction after zoledronic acid treatment in vivo. Scatter plots illustrating quantified breast cancer 
cell fraction (breast cancer cells/mg tumor) of in ovo tumors harvested on day 14 after a single gift of zoledronic acid (200 µM) or vehicle 
(PBS) on day 10. Tumors consisted of SCP2 alone or SCP2 with Hs27a stromal cells A. and MCF-7 alone or MCF-7 with Hs27a stromal 
cells B.. Breast cancer fraction is depicted for every individual tumor. Data are represented as mean ± SD.
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Stromal cells are required for anti-breast cancer 
cell effect by ZOL in vivo
In the in vivo CAM assay, we investigated the 
effect of ZOL in two different breast cancer suptypes; ER 
positive (MCF-7) and triple negative (SCP2) breast cancer. 
Tumors grown on the CAM assay consisted of tumor cells 
only, tumor cells mixed with Hs27a stromal cells or Hs27a 
cells only.
On day 14 of the in vivo CAM assay, vehicle-treated 
tumors containing SCP2 plus Hs27a cells were heavier 
(42.7 ± 14.7 mg vs 21.6 ± 10.3 mg, P < 0.001) and larger 
(55.5 ± 21.7 mm3 vs 31.8 ± 15.5 mm3, P < 0.05) compared 
to tumors containing only SCP2 cells (Figure 3A and 3B). 
Tumors containing only SCP2 cells had a higher weight 
after treatment with ZOL compared to vehicle (33.9 ± 
17.1 vs 21.6 ± 10.3 mg (P < 0.05). The tumor size was 
not affected by ZOL compared to vehicle treatment for 
tumors consisting of only SCP2 cells. However, tumors 
containing SCP2 plus Hs27a cells were sensitive to ZOL. 
On day 14, these tumors weighed less and were smaller 
when treated with ZOL compared to vehicle-treated SCP2 
plus Hs27a tumors (tumor weight: 23.0 ± 8.6 mg vs 42.7 
± 17.7 mg P < 0.01, size: 32.4 ± 19.8 mm3 vs 55.5 ± 21.7 
mm3 P < 0.05) (Figure 3A and 3B). 
ZOL treatment showed similar results for tumors 
consisting of only MCF-7 cells and tumors containing 
MCF-7 plus Hs27a cells. On day 14, tumors comprising 
MCF-7 plus Hs27a cells were heavier (36.9 ± 8.8 mg vs 
21.4 ± 6.2 mg P < 0.01) and larger (54.4 ± 15.5 mm3 vs 
18.6 ± 5.6 mm3 P < 0.001) (Figure 3C and 3D) compared 
to tumors consisting of only MCF-7 cells. Moreover, ZOL 
had no effect on tumors containing only MCF-7 cells. 
However, in tumors containing MCF-7 plus Hs27a cells, 
ZOL treatment resulted in reduced tumor weight and size 
compared to vehicle-treated tumors (weight: 23.5 ± 6.4 
mg vs 36.9 ± 8.8 mg P < 0.01, size: 28.2 ± 10.7 vs 54.4 
± 15.5 mm3 P < 0.01) (Figure 3C and 3D). ZOL did not 
affect size and weight of tumors containing only Hs27a 
cells (Suppl. Figure 1).
To verify that the reduction in both size and weight 
of tumors consisting of both breast cancer and stromal 
cells by ZOL was caused by loss of breast cancer cells, 
the breast cancer fraction of all tumors was determined. 
The breast cancer fraction accounts for the ratio of breast 
cancer cells on the total number of cells, multiplied by 
the weight of the tumor. The breast cancer cell fraction 
of tumors containing only SCP2 or MCF-7 cells was not 
affected by ZOL. However, the breast cancer cell fraction 
of SCP2 and MCF-7 tumors that also contained stromal 
cells was larger than SCP2 or MCF-7 cells only. ZOL 
reduced the breast cancer cell fraction of the co-cultured 
tumors (P < 0.01 SCP2, P < 0.05 MCF-7). Moreover, the 
size of ZOL-treated SCP2 and MCF-7 co-culture tumors 
was reduced compared to the size of their respective 
mono-culture tumors (Figure 4A and 4B). Hematoxylin 
& eosin (H&E) staining showed no difference in tumor 
viability between the tumor groups (Suppl. Figure 2).
Reduced TGF-β signaling in stromal cells is 
required for anti-breast cancer effect of ZOL
Total transforming growth factor (TGF)-β1 
excretion levels, both active and latent, in supernatant of 
stromal cells and co-cultures were reduced by 48 hours 
treatment with ZOL (Suppl. Table 1). Total TGF-β1 levels 
in supernatant of stromal cells decreased after treatment 
with 50, 100 and 500 µM ZOL (Figure 5A). In the 
supernatant of SCP2 co-cultured with Hs27a, total TGF-β1 
levels also decreased after treatment with ZOL 50 µM, 
100 µM and 500 µM (Figure 5B). In co-cultures of H2N 
with Hs27a and MCF-7 with Hs27a, total TGF-β1 levels 
were reduced after treatment of 100 µM and 500 µM ZOL 
(Figure 5C and 5D). However, 48 hours of ZOL treatment 
did not reduce total TGF-β1 levels in the supernatant 
of SCP2 and H2N breast cancer cells in the absence of 
stromal cells. In the supernatant of MCF-7 breast cancer 
cells without stromal cells, total TGF-β1 levels were 
undetectable ( < 0 ± 60 pg/mL) (data not shown). One day 
of ZOL treatment did not alter total TGF-β1 levels in the 
supernatant of monocultures of stromal Hs27a cells and 
SCP2, H2N and MCF-7 cells. This was also the case for 
the total TGF-β1 levels in the supernatant of co-cultures 
of stromal and breast cancer cells treated for 24 hours with 
ZOL (Suppl. Figure 3).
ZOL treatment resulted in dose-dependent increased 
death of SCP2 cells in co-culture with Hs27a cells in vitro 
(Figure 6A). The addition of pure active TGF-β1 to the in 
vitro co-culture model of SCP2 and Hs27a cells treated 
with ZOL almost completely abolished the ZOL-induced 
SCP2 cell death. Two days after the addition of pure active 
TGF-β1, SCP2 cell death decreased from 24.3 ± 2.9 % to 
9.5 ± 2.3 % (P < 0.001) for 10 µM ZOL, 35.6 ± 2.9 % to 
13.3 ± 2.5 % (P < 0.001) for 50 µM ZOL, 37.7 ± 2.9 % 
to 15.3 ± 3.8 % (P < 0.001) for 100 µM ZOL and 47.8 ± 
8.6 % to 32.9 ± 1.9% (P < 0.001) for 500 µM ZOL. The 
addition of pure active TGF-β1 to monocultures of SCP2 
cells treated with ZOL did not have this effect. 
Blocking of all TGF-β present in our culture models 
by a pan-TGF-β antibody resulted in SCP2 cell death 
only in the presence of Hs27a cells. At 24 hours of TGF-β 
antibody treatment, breast cancer cell death in co-culture 
with Hs27a was induced compared to untreated cells (10.9 
± 3.6% vs 4.06 ± 0.8% P < 0.01) (Figure 6C). In SCP2 
mono-cultures, TGF-β antibody treatment did induce 
SCP2 cell death compared to untreated SCP2 mono-
cultures.
Active TGF-β signaling activity in SCP2 breast 
cancer cells, measured by pSmad2 levels, was increased 
after incubation with Hs27a supernatant (Figure 6B). As 
a control, an excess of pure active TGF-β1 (5 ng/mL) was 
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added to the SCP2 cells and this also resulted in clear 
Smad2 phosphorylation. In contrast, supernatant of Hs27a 
cells treated with all dosages of ZOL decreased pSmad2 
levels. This indicates that ZOL can indirectly reduce active 
TGF-β signaling in breast cancer cells, via an effect on 
stromal cells. 
DISCUSSION
Our study provides functional proof that the 
bisphosphonate ZOL can exert an anti-breast cancer 
effect only in the presence of stromal cells. We 
investigated this in various breast cancer subtypes 
and two microenvironmental cell lines. These results 
complement research by Junankar et al. showing that 
Figure 5: TGF-β1 excretion after 48 hours of zoledronic acid treatment in vitro. Total TGF-β1 excretion (pg/mL) after 48 
hours of exposure to 0 – 500 µM zoledronic acid of Hs27a stromal cells in mono-culture A. or co-cultured with SCP2 B., H2N C. or MCF-
7 D.. Data are represented as mean ± SD.
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the bisphosphonates risedronate and pamidronate target 
macrophages in the breast cancer microenvironment 
of mouse 4T1 xenografts [6]. In their mouse model, 
intravital imaging revealed bisphosphonate uptake in 
calcium-rich tumor regions, while no uptake was seen 
in non-cancerous mouse mammary glands. Together 
with the data by Junankar et al., our study supports the 
concept of a microenvironment-mediated anti-tumor effect 
of bisphosphonates, and further clarifies the mechanism 
behind this effect. 
These results suggest that bisphosphonate treatment 
not only modulates the bone environment, but also affects 
non-bone disease. This is in line with clinical data. A 
recent meta-analysis showed that breast cancer recurrence 
decreased in early breast cancer patients treated with a 
bisphosphonate [4]. The clear interaction of ZOL with 
stromal cells in our study supports the broader effect of 
bisphosphonates outside of the bone environment. For 
future studies it will be of great interest to further study 
the anti-breast cancer effect of zoledronic acid exerted via 
other microenvironmental cell types. Furthermore, it will 
be relevant to evaluate these effects in a tissue specific 
context resembling for example the microenvironment of 
the primary tumor or a specific metastatic site.
Figure 6: Breast cancer cell death and TGF-β signaling after stromal treatment of zoledronic acid in vitro. A. Viability 
(%) of SCP2 mono-culture or co-culture with Hs27a stromal cells after 48 hours of treatment with 0 – 500 µM zoledronic acid with or 
without pure active TGF-β1 (1 ng/mL) quantified by fluorescent microscopy. B. Western blotting of pSmad2 was performed on lysates 
of SCP2 cells. β-actin serves as a loading control. SCP2 cells were incubated for 1 hour with medium, pure active TGF-β1 (5 ng/mL), or 
supernatant of Hs27a cells treated for 48 hours with 0 – 500 µM zoledronic acid. The relative density of the pSmad2 bands compared to the 
loading control is shown. C. Breast cancer cells death (%) of SCP2 mono-cultures or co-cultured with Hs27a stromal cells after 24 hours 
of treatment with anti- TGF-β antibody (10 ng/mL), determined by flowcytometric measurements of DiI and LIVE/DEAD stain. Data are 
represented as mean ± SD.
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Bisphosphonates inhibit osteoclast activity by 
inhibiting protein prenylation [11]. As inhibition of 
prenylation play would result in similar effects on breast 
cancer cell death, with and without stromal cells, this 
mechanism probably is not responsible for breast cancer 
cell death in our study. In our co-culture experiments, the 
reduced difference between breast cancer cells with an 
without stromal addition at the highest zoledronic acid 
concentration could be attributed to prenylation effects on 
the tumor cells. This is then in accordance with the IC50 
levels observed in the MTT assay.
In our co-culture model, treatment with zoledronic 
acid led to reduction of total TGF-β levels and active 
signaling activity. Moreover, treatment of breast cancer 
cells with an anti-TGF-β antibody instead of zoledronic 
acid induced breast cancer cell death only in the co-culture 
condition. These results indicate that reduced TGF-β 
signaling in breast cancer cells, as observed in co-culture 
after zoledronic acid treatment, can cause increased cell 
death of breast cancer cells. However, our results do not 
rule out that, apart from TGF-β, other factors could also be 
involved in this tumor-stroma interaction after zoledronic 
acid treatment. Moreover, the reason to why breast cancer 
cells, in co-culture compared to mono-culture after 
zoledronic acid treatment, are more dependent on TGF-β 
signaling remains to be elucidated. Previous research 
suggested a strong role for the microenvironment with 
respect to bisphosphonate sensitivity and TGF-β signaling 
[12]. In mice, bisphosphonate pamidronate treatment 
applied to established in-bone metastases of the cell 
line SCP28 evidently reduced active TGF-β signaling 
in these metastases. In that study, however, treatment of 
SCP28 tumor cells with pamidronate in vitro – without 
the presence of stromal cells – affected neither TGF-β 
signaling nor tumor cell death. Our study explains this 
apparent paradox by demonstrating the mediating role of 
the stromal cells. TGF-β transcriptional activity can also 
be inhibited by ER activation [13], thereby linking our 
research with pre-clinical and clinical studies showing that 
bisphosphonates only exert an anti-tumor effect under low 
estradiol concentrations [14, 15]. If, under high estradiol 
levels, TGF-β signaling is already repressed, adding 
another TGF-β suppressing agent like ZOL would have 
no additional anti-cancer effect. 
To our knowledge, ours is the first study to evaluate 
the effect of ZOL on the breast cancer-stroma interaction 
by assessing the separate components. This analysis was 
made possible by using the CAM model. Due to its low 
immunogenicity, xenografts can be grown on the CAM 
model up to day 18 of embryonic development [16]. 
Moreover, in the CAM model, growth of host stroma into 
the human xenograft is limited. In contrast, tumors of 
mice inoculated with human cell lines or patient-derived 
xenografts consist of around 40% mouse DNA [10, 17]. 
We observed good experimental reproducibility of the 
CAM assay between separate experiments.
In conclusion, the anti-breast cancer effect of ZOL 
is dependent on the presence of stromal cells. This is 
accompanied by decreased stromal cell TGF-β excretion 
and reduced TGF-β signaling in cancer cells. 
MATERIALS AND METHODS
Cell lines and reagents
The human cell lines used in this study were 
representing different breast cancer subtypes and two 
microenvironmental cell lines. ER positive breast cancer 
cell line MCF-7 and immortalized stromal cell line 
Hs27a (American Type Culture Collection (ATCC)) 
were cultured in Roswell Park Memorial Institute 
(RPMI) medium (Invitrogen), supplemented with 10% 
fetal calf serum (FCS). Hs27a cells were cultured up 
to a maximum of 30 passages during which these cells 
remained phenotypically stable and viable. Macrophage 
cell line RAW 264.7 was cultured in Dulbecco’s Modified 
Eagle Medium (DMEM) (Invitrogen) with 10% FCS and 
1% glutamine. The inflammatory triple negative breast 
cancer cell line SUM-149 (Asterand) was cultured in 
HAM’s Nutrient Mixture-F12 (HAM) supplemented with 
5% FCS, 5 µg/mL insulin and 1 µg/mL hydrocortisone. 
Triple negative breast cancer cell line MDA-MB-231 
(ATCC), the daughter cell line MDA-MB-231-H2N (H2N) 
(transfected to stably overexpress HER2) [18], luciferase 
transfected MDA-MB-231-SCP2 (SCP2) (provided by Dr 
Y Kang, Princeton University, NJ) [19] were cultured in 
DMEM with 10% FCS and 1% glutamine. Cell lines were 
cultured at 37 °C in a humidified atmosphere containing 
5% CO2 and were routinely tested for Mycoplasma. 
Short tandem repeat profiling (BaseClear) was used to 
authenticate the cell lines. 
Breast cancer and stromal cell proliferation in 
vitro in response to ZOL
Hs27a, RAW 264.7, MCF-7, MDA-MB-231, 
H2N, SCP2 and SUM-149 cells were plated in 96-
well plates with a density of 2,000 – 12,500 cells/
well. ZOL (SelleckChem) was added in different 
concentrations (1-1,000 µM) and cells were incubated 
for 96 hours. Thereafter, 3-(4,5-dimethylthiazol-2-
yl)-2,5- diphenyltetrazolium bromide (MTT) was added 
and formazan production as read out of cell number and 
metabolic activity was measured as described previously 
[20].
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Breast cancer cell death in an in vitro co-culture 
model in response to ZOL
This fluorescence-based in vitro co-culture model 
was described previously [21]. To distinguish the cancer 
cells from the stromal cells, SCP2 cells were pre-
labeled with fluorescent marker DiI (Molecular Probes, 
Invitrogen). Hs27a cells were grown as monolayer on 
glass slides inserted in 24-well plates. Subsequently, 
15,000 SCP2 cells were added per well, with or without 
a pre-cultured stromal cell monolayer and allowed to 
attach to the glass insert or the stromal layer for 24 hours. 
Attached cells were treated with ZOL (10 - 500 µM) 
for 24 or 48 hours. To study whether the effects of ZOL 
could be counteracted by TGF-β1, a condition with active 
TGF-β1 addition was included. The cells were cultured 
for 48 hours following the addition of 1 ng/mL pure active 
TGF-β1 (PeproTech) concurrently with ZOL. 
After incubation, the plates were centrifuged at 
300 g for 7 minutes. Glass slides were collected, fixed 
with methanol:acetone (1:1) and stained with 1:1000 
4’,6-diamidino-2-phenylindole (DAPI). The results 
were analyzed by fluorescent microscopy. Tumor cell 
viability was assessed with nuclear DAPI staining based 
on observation of the nuclear structure (intact versus 
fragmented nuclei). For each condition, 6 - 12 fields of 
view were counted and the average percentage of dead 
cells was calculated. 
Breast cancer cell death after ZOL treatment in 
presence and absence of stromal cells was determined 
by an additional method. Hs27a cells were grown as 
monolayer in 6-well plates. SCP2 cells were pre-labeled 
with fluorescent marker DiI and plated, with a cell density 
of 200,000 cells per well, on plates with or without 
pre-cultured stromal layer. Attached cells were treated 
with ZOL (10 - 500 µM) or a pan-TGF-ß antibody (10 
ng/mL) (R&D systems) for 24 hours. Cell death was 
determined by flowcytometry analysis after incubation 
with fluorescent LIVE/DEAD stain (Life Technologies) 
by manufacturer’s protocol as described before [22]. Cells 
positive for DiI and LIVE/DEAD stain were considered 
as dead breast cancer cells. Samples were acquired with 
FACS LSR II (Becton-Dickinson) and the percentage of 
double positive cells (dead breast cancer cells) compared 
to DiI positive cells (all breast cancer cells) was quantified 
by FlowJo (Tree Star, Inc.).
Breast cancer cell death in an in vivo co-culture 
model in response to ZOL
To study the effect of ZOL in vivo, the CAM model 
was used as described previously [23]. Two breast cancer 
models, SCP2 and MCF-7, were studied in this way. 
Eggs (het Anker BV) were incubated at 38°C and after 
3 days the CAM was lowered by puncturing the top of 
the eggs. On day 6 of embryonic development, a window 
was made in the egg shell to access the CAM. The CAM 
was damaged using a cotton tissue (Celltork) and each egg 
was inoculated with a total of 5·106 cells in 50 µL culture 
media and Matrigel (BD Biosciences) (1:1). On day 10 
of embryonic development, a 4 mm latex ring (Dentsply 
International) was placed on the CAM and 15 µL of ZOL 
(200 µM) or vehicle was pipetted in the ring. The dose 
ZOL used in the CAM assay was based on our in vitro 
experiments and concurs with a dosage of 16 μg/kg for 
an egg weighing on average 0.05 kg. This is a low dose 
compared to the clinic, where a patient receives a dose of 
4 mg concurring with a dosage of 53 μg/kg for a patient 
weighing 75 kg. 
 Each experiment comprised 3 subgroups; group 
1) breast cancer cells only, SCP2 or MCF-7 cells treated 
with ZOL (SCP2 n = 15, MCF-7 n = 6) or vehicle (SCP2 
n = 17, MCF-7 n = 8), group 2) Hs27a cells treated with 
ZOL (n = 8) or vehicle (n = 7) and group 3) a mixture 
of breast cancer cells, SCP2 or MCF-7, with Hs27a cells 
(1:1) treated with ZOL (SCP2 n = 17, MCF-7 n = 9) 
or vehicle (SCP2 n = 12, MCF-7 n = 6). On day 14 of 
embryonic development, tumors were harvested, weighed 
and measured with a caliper. 
Tumor tissue was formalin-fixed and paraffin 
embedded for immunohistochemical analyses. H&E 
staining was performed to analyze tissue viability and 
morphology. Slides (5 µm) were stained with an antibody 
against cytokeratin (CK) 8, 18 and 19 (Abcam 1:100). 
Substitution of the 1st antibody by bovine serum albumin 
was used as negative control. To calculate the breast 
cancer cell fraction in the tumors, the ratio of CK positive 
cells on the total number of cells was determined per 
tumor. Then this number was multiplied by the total tumor 
weight. 
Stromal and breast cancer TGF-β1 excretion in 
mono- and co-culture models in vitro in response 
to ZOL
Total TGF-β1 levels were determined in supernatant 
of Hs27a cells in mono-culture or in co-culture with MCF-
7, SCP2 or H2N cells after 24 and 48 hours incubation 
with ZOL. Cell culture supernatant was removed, 
centrifuged for 15 minutes at 240 g to remove any residual 
cells or cell remnants, and subsequently stored frozen 
in aliquots. Total TGF-β1 levels were measured with 
enzyme-linked immunosorbent assays (ELISA) according 
to manufacturer’s instructions (Quantikine, R&D 
Systems). The absorbance of each well was measured by 
a microplate reader (Bio-Rad). 
Oncotarget24446www.impactjournals.com/oncotarget
Breast cancer TGF-β signaling in vitro in response 
to ZOL
As read out for TGF-β signaling activity, protein 
expression of phosphorylated Smad2 was measured 
by Western blot. Hs27a cells were grown as monolayer 
and treated with ZOL (10 - 500 µM) for 48 hours. 
Subsequently, 500,000 SCP2 cells were plated in 6 wells 
plates and incubated for 24 hours. Pure active TGF-β1 
(5 ng/mL) or harvested supernatant of Hs27a cells was 
added to the confluent SCP2 cells. After 1 hour incubation, 
the supernatant was removed. Total cell lysates were size 
fractionated and transferred to a membrane as described 
previously [24]. 
Membranes were exposed to primary antibodies 
(anti-pSmad2; Cell Signaling Technology, anti-β-actin; 
MP Biomedicals). Binding of antibodies was determined 
using horseradish peroxidase (HRP)-conjugated secondary 
antibodies (DAKO) and visualized with Lumi-lightplus 
(Roche Diagnostics). Band density was evaluated by 
ImageJ software. 
Statistical analysis
Data are presented as mean ± SD. Statistical analysis 
was performed using the one-way or two-way ANOVA 
test with Tukey’s or Bonferroni’s post hoc test (GraphPad 
Prism, version 5). Differences were considered significant 
when P < 0.05.
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